| Market Cap | 239.45M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -83.84M | Forward P/E | -2.74 | EPS next Y | 4.70% | 50D Avg Chg | -27.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -38.00% |
| Dividend | N/A | Price/Book | 1.40 | EPS next 5Y | - | 52W High Chg | -60.00% |
| Recommedations | 1.70 | Quick Ratio | 8.11 | Shares Outstanding | 39.65M | 52W Low Chg | 7.00% |
| Insider Own | 8.62% | ROA | -39.66% | Shares Float | 20.99M | Beta | 1.97 |
| Inst Own | 79.51% | ROE | -70.12% | Shares Shorted/Prior | 546.62K/899.22K | Price | 6.71 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 79,748 | Target Price | 15.88 |
| Oper. Margin | - | Earnings Date | - | Volume | 57,074 | Change | -11.71% |
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
| Guggenheim | Buy | Aug 14, 24 |
| HC Wainwright & Co. | Buy | Aug 14, 24 |
| HC Wainwright & Co. | Buy | Jul 25, 24 |
| HC Wainwright & Co. | Buy | Jul 19, 24 |
| Wedbush | Outperform | Jul 11, 24 |
| Wedbush | Outperform | Jun 28, 24 |
| HC Wainwright & Co. | Buy | Jun 28, 24 |
| Wedbush | Outperform | May 8, 24 |
| HC Wainwright & Co. | Buy | May 8, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO President and CEO | Nov 20 | Buy | 3.75 | 4,000 | 15,000 | 207,687 | 11/20/23 |
| Papapetropoulos Spyros | Chief Medical Office.. Chief Medical Officer | Nov 18 | Option | 1.89 | 300 | 567 | 4,300 | 11/22/22 |
| Papapetropoulos Spyros | Chief Medical Office.. Chief Medical Officer | Nov 18 | Sell | 14 | 300 | 4,200 | 4,000 | 11/22/22 |
| Thorp Clay | Director Director | May 16 | Buy | 2.86 | 36,695 | 104,948 | 1,556,030 | 05/17/22 |
| Thackaberry Evan | SVP, Head of Early D.. SVP, Head of Early Development | May 05 | Buy | 4.00 | 1,500 | 6,000 | 1,500 | 05/06/22 |
| Verni Christopher | General Counsel General Counsel | May 03 | Buy | 3.7686 | 4,000 | 15,074 | 4,000 | 05/04/22 |
| Magovcevic-Liebisch Ivana | President and CEO President and CEO | May 02 | Buy | 3.77 | 5,000 | 18,850 | 203,687 | 05/04/22 |
| Ziolkowski Jennifer Lynn | Chief Financial Offi.. Chief Financial Officer | May 03 | Buy | 3.7744 | 4,000 | 15,098 | 4,000 | 05/04/22 |
| Papapetropoulos Spyros | Chief Medical Office.. Chief Medical Officer | May 03 | Buy | 3.3978 | 4,000 | 13,591 | 4,000 | 05/04/22 |
| Thorp Clay | Director Director | Jan 11 | Buy | 14 | 265,000 | 3,710,000 | 1,519,335 | 01/11/22 |
| Vida Ventures GP III, L.L.C. | 10% Owner 10% Owner | Jan 11 | Buy | 14 | 1,675,000 | 23,450,000 | 11,536 | 01/11/22 |
| Atlas Venture Fund XII, L.P. | 10% Owner 10% Owner | Jan 11 | Buy | 14 | 535,000 | 7,490,000 | 4,808,896 | 01/11/22 |
| Booth Bruce | Director Director | Jan 11 | Buy | 14 | 535,000 | 7,490,000 | 4,808,896 | 01/11/22 |
| Vitorovic Stefan | Director Director | Jan 11 | Buy | 14 | 1,675,000 | 23,450,000 | 11,536 | 01/11/22 |
| Northpond Ventures GP, LLC | 10% Owner 10% Owner | Jan 11 | Buy | 14 | 355,000 | 4,970,000 | 1,382,978 | 01/11/22 |